Lipoprotein(a)-Lowering Agent Fails to Reduce Cardiovascular Events
The experimental drug pelacarsen did not reduce the risk of adverse cardiovascular events in a phase 3 study, despite lowering lipoprotein(a) (Lp[a]) levels, the manufacturer announced.
We haven't written up this one. JAMA has the full story — the link below goes straight to it.